SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like Another Biotech Bites the Dust as Cambridge's Raze Shuts Down December 13, 2017 <b>Dr. Ottavio Vitolo</b> Appointed Executive Clinical Advisor At Relmada Therapeutics June 20, 2017 Cambridge's ImmusanT Nabs $40M November 13, 2017
